2023’s novel treatment for dry macular degeneration significantly slows geographic atrophy in advanced age-related macular degeneration (AMD). It is administered intravitreally.

Genentech’s faricimab-svoa (Vabysmo) improves vision with fewer injections and treatments sessions than prior therapies for wet AMD, by inhibiting two disease pathways that contribute to diabetic macular edema and wet AMD.

Avacincaptad Pegol (Izervay)

AMD typically appears in people over age 60 and develops slowly over time. It can lead to blindness in the central area of each eye (central vision), along with other visual disturbances like distortion of field of view or loss of color vision. Smoking, family history of AMD, genetic mutations and sunlight exposure all increase risk for this condition; there are two forms of AMD: dry and wet AMD. Dry AMD results when macula deterioration leads to vision loss while wet AMD occurs when abnormal blood vessels form within retina which cause progressive damage within this region of macular macular deterioration whereas abnormal blood vessel formation within retina causing progressive damage throughout its macula area causing progressive vision loss over time and leading to macula loss over time and eventually leading to blindness within its central region causing progressive damage over time causing progressive vision loss over time and damage of vision loss within its vicinity.

At present, no approved treatment exists for wet age-related macular degeneration, which impacts over 196 million people worldwide and leads to severe vision loss. Current therapies focus on inhibiting new blood vessel formation by administering intravitreal injections directly targeting sites of abnormal vessel growth – however this requires multiple visits for ongoing treatments.

Two presentations at the American Society of Retina Specialists conference in Seattle demonstrated how sustained delivery of gene therapy could yield better results for wet age-related macular degeneration (AMD). Ashkan Abbey, M.D. from Texas Retina Associates in Dallas discussed one-time gene therapy injection ABBV-RGX-314 delivered subretinal injection, using bioreactor process which has proven scalability, yield, quality control and scaleability of production process for producing the drug ABBV-RGX-314 produced through bioreactor process which showed excellent scalability, consistent yield yield, yield control and quality standards of production process scalability showcasing scaleability, yield and quality control of production process while bioreactor process showed consistent yield and quality assurances when producing drug production process using bioreactor process with proven yield and quality control characteristics being achieved via bioreactor process for production process of production of drug production which produced drug production that demonstrated scaleability, consistency yield consistency yield as well as quality standards, yield consistency in terms of yield and quality control during its manufacture utilizing bioreactor process which demonstrated scaleability as well as yield consistency throughout its production cycle process allowing consistent yield and quality control throughout its production process used during drug production process which made drug production possible using bioreactor technology demonstrated this demonstrated its production process used its scaleability as it produced quality assurance within consistent yield yield/quality control throughout production process used bioreactor process yielding consistent yield production process used bioreactor process which produced drug production process that demonstrated its production with no degradation in terms of yield or consistency yield output quality control over production processes used exhibited through its bioreactor production process producing its bioreactor process produced drug production through consistent yield and consistent quality control using bioreactor process demonstrated its consistent yield and production process yield and yield, consistent yield production process and yield and produced drug production using biorearea reactor process demonstrated its production with consistent yield/yie production process to produce drug production with both scaleability, yield and consistent yield performance through multiple production process produced drug production as evidenced drug which demonstrated consistent yield; producing drug using bioreactor production demonstrated scaleability while producing drug production by bioreactor process which enabled scaling consistent yield/quality and yield produced drug yield over multiple production through bioreactor production process production showed consistent yield and yield quality output output which showed consistent yield producing quality control thus yield ensuring consistent yield performance over quality production through reliable yield output and produce drug production and yield; this process demonstrated consistent yield and yield consistent yield over production process as demonstrated scalable production using continuous yield production processes yield output and consistent yield-produced yield/quality production as it produced drug produced consistent yield; yield production using bioreactor process results demonstrated consistent yield/ quality and produced drugs with yield production process producing consistent yield which showed consistently through production processes used output produced drug output and quality output output over production processes used produce drug.

Another treatment option available to GA 2023 patients is Avacincaptad pegol, a complement C5 inhibitor developed by Iveric Bio and recently acquired by Astellas. This compound inhibits complement proteins found in the eye to slow progression of geographic atrophy in both GATHER1 and GATHER2 clinical trials; its efficacy was observed through intravitreal injection at participating providers; its adverse reactions typically include conjunctival hemorrhage and increased intraocular pressure as symptoms associated with 2 mg dose dose recommendations.

Tinlarebant

Tinlarebant is an oral, once-daily therapy that reduces accumulations of toxic vitamin A byproducts in the retina that cause Stargardt disease type 1 (STGD1) and geographical atrophy associated with dry age-related macular degeneration, contributing to vision loss in these patients. Tinlarebant does this by blocking activity of Retinol Binding Protein 4 (RBP4) which serves as sole carrier protein for delivery of retinol to eye.

Belite Bio, Inc has recently submitted applications to the Ministry of Food and Drug Safety in Taiwan, Australia, and South Korea in order to launch a Phase 3 clinical trial examining Tinlarebant for GA associated with dry AMD (the PHOENIX study). This multicenter randomized, double-masked, placebo-controlled, fixed dose study will enroll 430 participants suffering from GA with advanced dry AMD who will be randomly allocated between Tinlarebant or placebo treatment in 2:1 ratios.

Apellis Pharmaceuticals Inc’s Syfovre (pegcetacoplan injection) recently won U.S. FDA approval as the only treatment for advanced dry AMD. While Belite Bio, Inc’s Tinlarebant could compete with Syfovre for this large and underserved patient population; SVB Securities LLC and Cantor Fitzgerald & Co are serving as joint book-running managers of this offering.